Friday - April 11, 2025
Eneboparatide Met Primary Endpoint of Normalizing Serum Calcium in Adults With Hypoparathyroidism at 24 Weeks in CALYPSO Phase III Trial
March 17, 2025
WILMINGTON, Delaware, March 17 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Eneboparatide met primary endpoint of normalizing serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial

Trial continues as planned to 52 weeks to further characterize the risk-benefit profile

High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigation . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products